From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
CD73-IN-4 is a potent and selective methylenephosphonic acid CD73 inhibitor, with an IC50 of 2.6 nM for human CD73. CD73-IN-4 is potential for the research of cancer immunology .
CD73-IN-3 is a potent CD73 inhibitor (IC50=7.3 nM in Calu6 human cell assay). CD73-IN-3, example 2 extracted from patent WO2019168744 A1, has the potential for cancer research .
5′-Nucleotidase, Microorganism (CD73) is an intrinsic membrane glycoprotein present as an ectoenzyme. 5′-Nucleotidase catalyzes hydrolysis of 5-nucleotides to their corresponding nucleosides .
CD73-IN-13 is a potent inhibitor of CD73. CD73 is closely associated with tumor growth, angiogenesis and metastasis. CD73-IN-13 be used for preparing a medicament for tumor-related diseases (extracted from patent CN114437039A, compound 7) .
CD73-IN-12 is a potent inhibitor of CD73. CD73 is closely associated with tumor growth, angiogenesis and metastasis. CD73-IN-12 be used for preparing a medicament for tumor-related diseases (extracted from patent CN114437038A, compound 9) . CD73-IN-12 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
CD73-IN-7 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-7 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022052886A1, compound 13) .
CD73-IN-8 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-8 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022052886A1, compound 57) .
CD73-IN-9 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-9 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 2) .
CD73-IN-11 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-11 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 24) .
CD73-IN-10 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-10 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 4) .
D73-IN-14 is a potent, selective and orally active CD73 inhibitor with an IC50 value of 0.17 nM. CD73-IN-14 increases the number of tumor-infiltrating CD8 + cells and shows anti-tumor activity . CD73-IN-14 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
PD-L1/CD-73-IN-1 (compound CC-5) is PD-L1/CD73 inhibitor with IC50 values of 6 nM and 0.773 μM to PD-L1 and CD73, respectively. PD-L1/CD-73-IN-1 inhibits tumor cell growth in vivo and in vitro .
ST80 is an inhibitor for interaction of OTUD4 and CD73. ST80 decreases CD73 protein level, increases CD73 protein turnover, reduces immune evasion of tumor cells, and thus exhibits antitumor efficacy against immunosuppressive triple-negative breast cancer (TNBC) .
OP-5244 is a potent and orally active inhibitor of CD73, with an IC50 of 0.25 nM. OP-5244 reverses immunosuppression through blocking of adenosine production, and has the potential for the cancer research .
OP-5244 sodium is a potent and orally active inhibitor of CD73, with an IC50 of 0.25 nM. OP-5244 sodium reverses immunosuppression through blocking of adenosine production, and has the potential for the cancer research .
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity .
Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer .
ZM514 is a potent CD73 inhibitor with IC50s of 1.39 μM and 14.65 μM for hCD73 and mCD73, respectively. ZM514 has low cytotoxicity. ZM514 can be used for researching anticancer .
AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity .
AB-680 ammonium is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity .
ORIC-533 is an orally active, selective CD73 inhibitor with AMP-competition. ORIC-533 restores immunosuppressed CD8+ T cell proliferation and activation, triggers significant lysis and cell death of multiple myeloma cells in the bone marrow microenvironment .
BK50164 is a potent CD73 inhibitor with an IC50 value of 13.089 µM. BK50164 binds to CD99 with a KD value of 1.5 µM. BK50164 shows antiproliferative activity. BK50164 induced Apoptosis and cell cycle arrest at Sub-G1 phase .
ARL67156 (FPL 67156) trisodium is a selective small molecular inhibitor, targeting to ecto-ATPase, CD39, and CD73. ARL67156 trisodium is also a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with Kis of 11, 18 and 12?μM, respectively. ARL67156 trisodium can be used in the research of calcific aortic valve disease, asthma .
ARL67156 (FPL 67156) trisodium hydrate is a selective small is a selective samll molecular inhibitor, targeting to ecto-ATPase, CD39, and CD73. ARL67156 trisodium hydrate is also a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with Kis of 11, 18 and 12?μM, respectively. ARL67156 trisodium hydrate can be used in the research of disease like calcific aortic valve disease, asthma .
ARL67156 (FPL 67156) triethylamine is a selective small is a selective samll molecular inhibitor, targeting to ecto-ATPase, CD39, and CD73. ARL67156 triethylamine is also a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with Kis of 11, 18 and 12?μM, respectively. ARL67156 triethylamine can be used in the research of disease like calcific aortic valve disease, asthma .
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity .
Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer .
CD73/5'-Nucleotidase Protein Protein, Mouse (HEK293, His) is a recombinant mouse CD73 expressed by HEK293 cells with His tag. CD73 is a cell surface enzyme that catalyzes the dephosphorylation of extracellular AMP to adenosine.
CD73/5'-Nucleotidase Protein, Rat (HEK293, His) is a 70-90 kDa rat CD73 protein with His-flag expressed by HEK293. Rat CD73 is a cell membrane protein that catalyzes the conversion of purine and pyrimidine ribo- and deoxyribonucleoside monophosphates to the corresponding nucleosides.
CD73/5'-Nucleotidase Protein, Cynomolgus (HEK 293, His) is a CD73 protein with a His-flag. CD73/5'-Nucleotidase Protein a zinc-dependent, 70 kDa homodimeric enzyme that binds to the cell membrane through a glycosyl phophatidylinositol (GPI) anchor.
CD73/5'-Nucleotidase Protein hydrolyzes nucleotide monophosphates, favoring AMP as the primary substrate and showing a preference for ribonucleotide monophosphates. It releases inorganic phosphate and the corresponding nucleoside. CD73 also acts on other substrates, including IMP, UMP, GMP, CMP, dAMP, dCMP, dTMP, NAD, and NMN. CD73/5'-Nucleotidase Protein, Human (HEK293, His) is the recombinant human-derived CD73/5'-Nucleotidase protein, expressed by HEK293 , with C-6*His labeled tag.
CD73/5'-Nucleotidase Protein hydrolyzes nucleotide monophosphates, favoring AMP as the primary substrate and showing a preference for ribonucleotide monophosphates. It releases inorganic phosphate and the corresponding nucleoside. CD73 also acts on other substrates, including IMP, UMP, GMP, CMP, dAMP, dCMP, dTMP, NAD, and NMN. CD73/5'-Nucleotidase Protein, Human (T376A, M379T, HEK293, His) is the recombinant human-derived CD73/5'-Nucleotidase protein, expressed by HEK293 , with C-6*His labeled tag.
CD73/5'-Nucleotidase Protein hydrolyzes nucleotide monophosphates, favoring AMP as the primary substrate and showing a preference for ribonucleotide monophosphates. It releases inorganic phosphate and the corresponding nucleoside. CD73 also acts on other substrates, including IMP, UMP, GMP, CMP, dAMP, dCMP, dTMP, NAD, and NMN. CD73/5'-Nucleotidase Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived CD73/5'-Nucleotidase protein, expressed by HEK293 , with C-His labeled tag.
CD73/5'-Nucleotidase Protein hydrolyzes nucleotide monophosphates, favoring AMP as the primary substrate and showing a preference for ribonucleotide monophosphates. It releases inorganic phosphate and the corresponding nucleoside. CD73 also acts on other substrates, including IMP, UMP, GMP, CMP, dAMP, dCMP, dTMP, NAD, and NMN. CD73/5'-Nucleotidase Protein, Human (T376A, HEK293, Fc) is the recombinant human-derived CD73/5'-Nucleotidase protein, expressed by HEK293 , with C-hFc labeled tag.
CD73 Antibody (YA528) is a non-conjugated and Rabbit origined monoclonal antibody about 63 kDa, targeting to CD73. It can be used for WB,IHC-P assays with tag free, in the background of Human.
CD73 Antibody (YA797) is a non-conjugated and Mouse origined monoclonal antibody about 63 kDa, targeting to CD73. It can be used for WB,IHC-P,IF,FC assays with tag free, in the background of Human.
CD73 is a 70 kD glycophosphatidylinositol (GPI)-linked 5'-nucleotidase, which is also known as ecto-5'-nucleotidase. It converts adenosine monophosphate (AMP) to adenosine. CD73 is expressed on subsets of T and B cells, mesenchymal stem cells, follicular dendritic cells, endothelial cells, and epithelial cells. It has been reported that CD73 costimulates T cell activation, and mediates adhesion of lymphocytes to follicular dendritic cells and endothelial cells.
D73-IN-14 is a potent, selective and orally active CD73 inhibitor with an IC50 value of 0.17 nM. CD73-IN-14 increases the number of tumor-infiltrating CD8 + cells and shows anti-tumor activity . CD73-IN-14 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Inquiry Online
Your information is safe with us. * Required Fields.
